ARS Pharmaceuticals, Inc. cotiza a 4.06 USD y tiene una capitalización bursátil de $404M. En los últimos 12 meses ha facturado $117M con un margen de flujo de caja libre del -203.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reaction…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.61 | $-0.42 |
| Estimado | $-0.33 | $-0.49 | $-0.53 | $-0.48 |
| Sorpresa | — | — | -15.1% | +12.5% |
| Métrica | SPRY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -212.9% | -38.6% | -174.3% |
| Net Margin | -203.3% | -33.6% | -169.7% |
| FCF Margin | -203.1% | -13.9% | -189.3% |
| ROE | -149.9% | -40.4% | -109.5% |
| ROA | -52.3% | -32.0% | -20.3% |
| Current Ratio | 7.28 | 2.84 | +4.44 |
| Debt / Equity | 0.84 | 0.28 | +0.56 |